ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe
On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions. One of the concerns was how the price, which didn’t accompany the original company press statement, would be critical for whether dolutegravir finds a significant market.
While (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 21, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study
GSK744, an investigational integrase inhibitor, and TMC278 LA (a long-acting, injectable form of the NNRTI rilpivirine [Edurant]) both showed safety and efficacy when administered in once-monthly or once-quarterly doses, according to a study presented at IAS 2013. There were no drug-related serious adverse events and all adverse events were either mild or moderate.
The phase 1 study, conducted (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 7, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Calimmune Initiates HIV Stem Cell Study at Two California Research Sites
(Los Angeles, CA) --
The
HIV gene medicines company Calimmune announced
today
that
the
first patient
has
begun treatment in
a Phase I/II
clinical trial designed
to determine
whether a pioneering genetic medicine approach can help to protect
individuals infected with
HIV from the effects of
the
virus. The study, “Safety Study of a Dual
Anti-HIV Gene Transfer Construct to Treat
HIV-1 Infection (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 9, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications
A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 9, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen
"Both the surviving patients had been receiving prolonged antiretroviral therapy and received stem cell transplants with a reduced-intensity conditioning regimen of chemotherapy designed to eradicate the cancer and eliminate the existing bone marrow. In the case of the two patients under investigation, the conditioning regimen did not include radiotherapy and it did not eliminate the (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 3, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent
Argos Therapeutics Announces Plans for HIV Eradication Study
"To create AGS-004, ribonucleic acid (RNA) is isolated from HIV particles obtained from patients, and dendritic cells are generated from a single leukapheresis procedure. Selected RNAs are then used to "program" the dendritic cells with the patient-specific payload to trigger an immune response against the patient's HIV infected (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 1, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Free 2013 Report: New HIV, HCV and TB Drugs, Diagnostics, and Vaccines in the Research Pipeline
HIV i-Base/Treatment Action Group 2013 Pipeline Reportcalls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible– Survey shows HIV pipeline healthy, HCV drug development surging,while TB research moves forward much too slowly –– Faster research, approval, and access demanded –
KUALA LUMPUR, Malaysia, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 30, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Supreme Court strikes down DOMA
The gay rights movement saw a significant victory at the Supreme Court Wednesday, where the justices struck down part of a law that prohibits federal recognition of same-sex marriages.
In a 5-4 ruling, the court struck down Section 3 of the 17-year-old Defense of Marriage Act (DOMA), a provision of the law that denies federal benefits -- like Social Security benefits or the ability to file (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 26, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
ResearchMatch Connects HIV Study Volunteers with Researchers
I highly encourage everyone to join our important attempt to accelerate the cure of HIV. Research Match also helps connect patients with other diseases with private investigators. Please forward to your friends and families. Anyone can participate.
Thank you in advance for supporting this platform!
Contact: Kathy Edson
(615) 343-2571/ kathleen.edson@vanderbilt.edu (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 6, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Sangamo biosciences presents clinical data demonstrating hiv reservoir reduction in hiv-infected subjects treated with modified immune cells with zinc finger nucleases
SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-TUnprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 TrialsRichmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - May 15, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Report from CROI-2013- My Personal Picks
CROI 2013 Report
Nelson Vergel
I was happy to attend
CROI-2013 in Atlanta on March 3-6, 2013. These are areas of great interest to me and
in no way attempts to summarize the main findings reported at the conference.
For abstract information, refer to http://www.retroconference.org/AbstractSearch/default2.aspx?conf=22
A baby girl gets cured (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 30, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
PoWeR YouTube Health Videos
Click Here For Videos (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 12, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Timing and T-Cells: The Evolution of When to Start Treatment Through One Doctor's Eyes - TheBodyPRO.com
http://www.thebodypro.com/content/71010/timing-and-t-cells-the-evolution-of-when-to-start-.html?ic=700100
Regards,
Nelson
Sent from my phone so please excuse misspellings and brevity (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 4, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy
AIDS:
12 April 2002 - Volume 16 - Issue 6 - pp 934-937
Research Letters
Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy
Collazos, Julio; Martinez, Eduardo; Mayo, José; Ibarra, Sofia
Free Access
Article Outline
Author Information
Section of Infectious Diseases, Hospital de Galdakao, Vizcaya, Spain.
Received: 3 August 2001; (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 18, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)
All of the presentations in this section were great.
The one on new drugs is contained in the last set of slides (blue slides at 1:22:46)
http://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo
For individual reports on each drug (Thanks to Natap.org):
NEW HIV DRUGS at CROI
Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 14, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs
